Despite these advances, several challenges hinder the clinical application of CRISPR-Cas9 in FGF19/FGFR4-targeted cancer therapy, including off-target effects, low in vivo delivery efficiency, immunogenicity, uncertain DNA repair mechanisms, and low homology-directed repair efficiency in non-dividing cells 286-288. The gene discussed is FGF19; the disease is cancer.